The new thinking on lipids and coronary artery disease

Current Opinion in Cardiology

Volumn 12, Issue 2, 1997, Pages 180-187

  Superko, H Robert ^a  

^a Berkeley HeartLab Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; TRIACYLGLYCEROL;

ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL;

EID: 0030961703     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199703000-00015     Document Type: Article

References (65)

1. Superko HR: What can we learn about dense LDL and lipoprotein particles from clinical trials? Curr Opin Lipidol 1996, 7:1-6. This paper reviews aspects of clinical trials that provide insight into patient treatment lessons gleaned from large clinical trials.
2. Forrester JS, Merz NB, Bush TL, Conn JN, Hunninghake DB, Parthasarathy S. Superko HR, for Task Force 4: Efficacy of risk factor management. J Am Coll Cardiol 1996, 27:991-1006. This publication is a current review of many aspects pertaining to preventive cardiology.
3. Gofman JW, Young W, Tandy R: Ischemic heart disease, atherosclerosis and longevity. Circulation 1966, 34:679-697.
4. Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Ann Int Med 1979, 90:85-91.
5. Alderman EL, Haskell WL, Fair JM, Superko HR, Maron DJ, Champagne MA, Mackey SF, Williams PT, Krauss RM, Farquhar JW: Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994, 89:975-990.
6. Phillips NR, Waters D, Havel RJ: Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
8. Gordon DJ, Knoke J, Probstfield JL. Superko HR, Tyroler HA: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1 986, 74:1217-1225.
9. Frick MH, Elo O, Haapa K, Heinonen P, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al.: Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237-1245.
10. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992, 85:37-45.
11. Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991, 11:2-14.
12. Superko HR: New aspects of cardiovascular risk factors including small, dense LDL, homocysteinemia, and Lp(a). Curr Opin Cardiol 1995, 10:347-354. A review of many of the inherited disorders contributing to CAD risk.
13. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5:339-349. A review of the small dense LDL issue up to 1994.
14. Slyper AH: Low-density lipoprotein density and atherosclerosis: unrav-eling the connection. JAMA 1994, 272:305-308.
15. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
16. Nishma PM, Johnson JP, Naggert JK, Krauss RM: Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci U S A 1992, 89:708-712.
17. Rotter JI, Bu X, Cantor R, Warden CH, Zia YR, De Meester C, Teryua S, Lockensgard B, Daneshmand S, Brown J, et al.: Multilocus genetic determination of LDL particle size in coronary artery disease families [abstract]. Clin Res 1994, 42:16A.
18. Stampfer MJ, Krauss RM, Blanche PJ, Holl LG, Sacks FM, Hennekens CH: A prospective study of triglyceride level, low density lipoprotein particle diameter and risk of myocardial infarction. JAMA 1996, 276:882-888.
19. Gardner CD, Fortmann SP, Krauss RM: Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women. JAMA 1996, 276:875-881.
20. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Circulation 1997, 95:69-75.
21. Phillips NR, Waters D, Havel RJ: Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
22. Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb Vasc Biol 1996, 16:697-704.
23. Miller BD, Krauss RM, Cashin-Hemphill L, Blankenhorn DH: Baseline triglyceride levels predict angiographie benefit of colestipol plus niacin therapy in the Cholesterol-Lowering Atherosclerosis Study (CLAS). Circulation 1993, 88:1-363.
24. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461-1467.
25. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM: Predominance of dense low-density lipoprotein particles predicts angiographic benefit or therapy in the Stanford Coronary Risk Intervention project. Circulation 1996, 94:2146-2153. Recent analysis of LDL subclasses and their impact on arteriographic change.
26. Superko HR: Lipid disorders contributing to coronary heart disease: an update. Curr Probl Cardiol 1996, 21:733-780. A recent review of inherited lipoprotein disorders and clinical trial results.
27. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation 1993, 87:113-1116.
28. Fuster V, Lewis A: Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994, 90:2126-2146. An excellent review of the plaque stability /instability issue.
29. Morerio PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Circulation 1994, 90:775-778.
30. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L: Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994, 23:1562-1569.
31. Brown BG, Zhao XQ, Sacco DE, Albers JJ: Lipid lowering and plaque regression. Circulation 1993, 87:1781-1791.
32. Superko HR: Inherited disorders in the lipoprotein system: a common cause of premature heart disease. In Women and Heart Disease. Edited by Julian DG, Wenger NK. London: Martin Dunitz; 1996: in press.
33. Dawber TR: The Framingham Study. Cambridge: Harvard University Press; 1980.
34. Genest JJ, Martin-Munley SS, McNamara JR, Ordavas JM, Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ: Familial lipoprotein disorders in patients with premature CAD. Circulation 1992, 85:2025-2033.
35. Friedlander Y: Familial clustering of coronary heart disease: a review of its significance and role as a risk factor for the disease. In Genetic Factors in Coronary Heart Disease. Edited by Goldbourt U, de Faire U, Berg K, Hingham, MA: Kluwer Academic Publishers; 1994:37-53.
36. Hamsten A, de Faire U: Risk factors for coronary artery disease in families of young men with myocardial infarction. Am J Cardiol 1987, 59:14-19.
37. Rissanen AM: Familial occurrence of coronary heart disease: effect of age at diagnosis. Am J Cardiol 1979, 44:60-66.
38. Friedlander Y, Lev-Merom D, Kark JD: Family history as predictor of incidence of acute myocardial infarction: The Jerusalem Lipid Research Clinic [abstract]. The 2nd International Conference on Preventive Cardiology and the 29th Annual Meeting of the AHA Council on Epidemiology. American Heart Association. Washington, DC USA June 18-22, 1989.
39. Sholtz RI, Rosenman RH, Brand RJ: The relationship of reported parental history to the incidence of coronary heart disease in the Western Collaborative Group Study. Am J Epidemiol 1975, 102:350-356.
40. Colditz GA, Rimm EB, Giovannucci E, Stampfer MJ, Rosner B, Willett WC: A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol 1991, 67:933-938.
41. Barrett-Connor E, Khaw K: Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation 1984, 69:1065-1069.
42. Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH: A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol 1986, 123:48-58.
43. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB: Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989, 64:555-559.
44. Phillips AN, Shaper AG, Pocock SJ, Walker M: Parental death from heart disease and the risk of heart attack. Eur Heart J 1988, 9:243-251.
45. Hopkins PN, Williams RR, Kuida H, Stults BM, Hunt SC, Barlow GK, Owen-Ash K: Family history as an independent risk factor for incident coronary artery disease in a high risk cohort in Utah. Am J Cardiol 1988, 62:703-707.
46. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U: Genetic susceptibility to death from coronary artery disease in a study of twins. N Engl J Med 1994, 330:1041-1046.
47. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G: Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary artery disease in patients with familial hypercholesterolemia. W Engl J Med 1990. 322:1494-1499.
48. Lipid Research Clinics Writing Groups: The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
49. Hjermann I, Holme I, Velve BK, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981, 11:1303-1310.
50. Shepherd J, Cobbe SM, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
51. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, and ACAPS: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994, 90:1679-1687.
52. Coronary Drug Project: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
53. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischemic heat disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
54. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 349:1383-1389.
55. Pitt B, Mancini J, Ellis S, Rosman HS, Park JS, McGovern ME, PLAC I Investigators: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I). J Am Coll Cardiol 1995:1133-1139.
56. Grouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995, 75:455-459.
57. Jukema JW, Bruschke VG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI and REGRESS Study Group: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995, 91:2528-2540.
58. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer WV, Mahrer PR, Masteller MJ, Vailas LI, et al., and MARS Research Group: Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993, 119:969-976.
59. Multicentre Antiatheroma Study Investigators: Effect of Simvastatin on coronary atheroma: the Multicentre Antiatheroma Study (MAAS). Lancet 1994, 344:633-638.
60. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, the Canadian Coronary Atherosclerosis Intervention Trial Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994, 89:959-968.
61. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992, 339:563-569
62. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary heart disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
63. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA 1990, 264:3013-3017
64. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hobert E, Drinkmann A, Bacher F, Grunze M, Kubler W: Regular physical exercise and low-fat diet: effects on progression of coronary artery disease. Circulation 1992, 86:1-11.
65. Buchwald H, Campos CT, Boen JR, Nguyen PA, Williams SE: Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia. J Am Coll Cardiol 1995, 26:351-357.